ArrowMark Colorado Holdings LLC Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

ArrowMark Colorado Holdings LLC reduced its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 13.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 882,731 shares of the biopharmaceutical company’s stock after selling 136,626 shares during the period. ArrowMark Colorado Holdings LLC owned 1.55% of Agios Pharmaceuticals worth $39,220,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in AGIO. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter worth approximately $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares during the period. CWM LLC grew its stake in shares of Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $146,000.

Agios Pharmaceuticals Stock Up 1.2 %

Shares of AGIO stock opened at $59.39 on Monday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The business has a fifty day simple moving average of $48.68 and a 200-day simple moving average of $45.49. The stock has a market cap of $3.39 billion, a P/E ratio of 5.23 and a beta of 0.75.

Wall Street Analysts Forecast Growth

AGIO has been the topic of a number of analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Friday, November 1st. Raymond James reissued an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Finally, Scotiabank lifted their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Insiders Place Their Bets

In related news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. The trade was a 11.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.93% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.